The European Commission has granted centralised marketing authorisation for Dexdor® (dexmedetomidine), indicated for sedation of adult intensive care unit (ICU) patients requiring a sedation level not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale 0 to -3).
Dexdor® (dexmedetomidine) is now licensed across all 27 countries in the European Union.
The active substance of dexdor® is dexmedetomidine, a sedative agent originated by Orion Corporation’s pharmaceutical R&D.
Dexmedetomidine is available with the brand name Precedex® in more than 30 countries outside Europe, including the USA (since 2000) and Japan (since 2004).
The distributor for the product outside Europe is Hospira, under Orion’s license.